All
Expert Addresses Importance of Tailored Therapy in Colorectal Cancer
May 1st 2017Axel Grothey, MD, addresses the need for tailoring treatments for patients with mCRC in the first-line setting, the debate over tumor sidedness in mCRC, and what ongoing research in the field might reveal over the next year.
Midostaurin Approved by FDA for AML
April 28th 2017Midostaurin (Rydapt) has been approved by the FDA for the treatment of adult patients with newly diagnosed <em>FLT3</em>-positive acute myeloid leukemia (AML) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Osimertinib Granted Full Approval by EU for EGFR T790M-Positive NSCLC
April 27th 2017Osimertinib has been granted a full approval by the European Union for the treatment of patients with locally advanced or metastatic <em>EGFR T790M </em>mutation-positive non–small cell lung cancer, regardless of prior treatment with an EGFR TKI.
The Future of MCL Treatment Is More Sophisticated, Nuanced, Expert Says
April 26th 2017Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.
Expert Reflects on Immunotherapy's Milestone Impact in NSCLC, and Questions That Still Remain
April 25th 2017Immunotherapy has made a significant impact in the field of non–small cell lung cancer. However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced disease.
Researchers Encouraged by Leiomyosarcoma Patient's Dramatic Response to Pembrolizumab
April 25th 2017Researchers at Dana-Farber Cancer Institute have identified an exceptional responder to pembrolizumab – a treatment-naïve patient with metastatic uterine leiomyosarcoma who had a complete tumor remission for more than 2 years on the PD-1 inhibitor.
AFP Level Identified as a Potential Biomarker for Survival in HCC
April 24th 2017According to an assessment of a large global dataset reported at the 2017 International Liver Congress, log<sub>10</sub> alpha fetoprotein level in the blood directly corresponded to the years of posttreatment survival in patients with hepatocellular carcinoma.
SIRT May Be Better-Tolerated Alternative to Sorafenib in Advanced HCC, Study Findings Show
April 24th 2017In patients with hepatocellular carcinoma, liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated, but the therapy did not improve rates of overall or progression-free survival over sorafenib.
Higher Risk of HCC Recurrence Observed Following DAA Therapy for Hepatitis C
April 21st 2017In updated results presented at the 2017 International Liver Congress, Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.
PFS Extended With Consolidation Therapy in Multiple Myeloma
April 21st 2017Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD) extended progression-free survival in patients with multiple myeloma when used in conjunction with stem cell transplantation compared with RVD alone